Table 3.
Epidemiological and Baseline Clinical Features of 249 Discharged COVID-19 Patients in the Third People's Hospital of Shenzhen until February 24, 2020
| Characteristics | COVID-19 Patients |
p-alue | ||
|---|---|---|---|---|
| Total (N = 249) | ≤20 days (n = 121) | >20 days (n = 128) | ||
| Age (years), median (IQR) | 44 (32–57) | 36 (25–53) | 50 (38–61) | <0.001 |
| Age subgroups | ||||
| 0–17 years | 21 (8.4) | 17 (14.0) | 4 (3.1) | – |
| 18–60 years | 175 (70.3) | 84 (69.4) | 91 (71.1) | – |
| >60 years | 53 (21.3) | 20 (16.5) | 33 (25.8) | – |
| Male (%) | 121 (48.6) | 57 (47.1) | 64 (50.0) | 0.74 |
| BMI (kg/m2) | 23.26 (21.26–25.22) | 23.25 (21.33–25.15) | 23.26 (21.26–25.28) | >0.99 |
| Initial symptoms | ||||
| Fever | 173 (69.5) | 71 (58.7) | 102 (79.7) | <0.001 |
| Cough | 95 (38.2) | 43 (35.5) | 52 (40.6) | 0.49 |
| Expectoration | 3 (1.2) | 2 (1.7) | 1 (0.8) | 0.61 |
| Headache | 9 (3.6) | 3 (2.5) | 6 (4.7) | 0.50 |
| Myalgia | 8 (3.2) | 3 (2.5) | 5 (3.9) | 0.72 |
| Chill | 1 (0.4) | 0 | 1 (0.8) | >0.99 |
| Nausea or vomiting | 1 (0.4) | 0 | 1 (0.8) | >0.99 |
| Diarrhea | 6 (2.4) | 2 (1.7) | 4 (3.1) | 0.68 |
| Co-existing chronic medical conditions | ||||
| Chronic heart disease | 7 (2.8) | 4 (3.3) | 3 (2.3) | 0.72 |
| Chronic lung disease | 3 (1.2) | 1 (0.8) | 2 (1.6) | >0.99 |
| Chronic renal disease | 6 (2.4) | 2 (1.7) | 4 (3.1) | 0.68 |
| Chronic liver disease | 21 (8.4) | 10 (8.3) | 11 (8.6) | >0.99 |
| Diabetes | 12 (4.8) | 4 (3.3) | 8 (6.3) | 0.43 |
| Hypertension | 29 (7.6) | 7 (5.8) | 12 (9.4) | 0.41 |
| Cancer | 1 (0.4) | 0 | 1 (0.8) | >0.99 |
| Exposure history | ||||
| Traveling history to Hubei | 197 (79.1) | 91 (75.2) | 106 (82.8) | 0.19 |
| Interval (days), median (IQR) | ||||
| Onset to admission | 3 (1–5) | 2 (1–4) | 4 (2–7) | <0.001 |
| Onset to diagnosis | 2 (0–4) | 1 (0–3) | 3 (1–6) | <0.001 |
Values are number (%) except where indicated otherwise. p values indicate differences between onset to discharged date ≤20 days and >20 days. p < 0.05 was considered statistically significant.